dsDNA Antibody ELISA Kit

One of the most prevalent viruses on Earth is double-stranded DNA (dsDNA), which frequently infects bacteria and leads to a wide range of illnesses. It is a major factor in difficulties that arise after stem cell and solid organ transplants. Double-stranded DNA (dsDNA) is significant in clinical care and research because of its stability and functional diversity. One common type of systemic autoimmune disease that can impact nearly every organ system is systemic lupus erythematosus or SLE. Hemolytic anemia, arterial and venous thrombosis, disfiguring rashes, and renal failure are only a few of the many clinical symptoms of systemic lupus erythematosus. In 2000, the general population had an approximate prevalence of 1 SLE patient, with a much larger proportion of female patients than male patients (about 6–10:1). Although the incidence is relatively low, the disease typically affects younger patients and is severe, leading to significant healthcare and social costs. The key immune dysregulation in SLE involves the production of autoantibodies against cell membrane and nuclear components, with anti-dsDNA antibodies detectable in 40-60% of SLE patients. These antibodies can be detected before the clinical symptoms of SLE appear.

Figure 1. The mechanism by which endogenous double-stranded DNA contributes to the pathogenesis of systemic lupus erythematosus (SLE) (Source: Bai Y, et al., 2018)

In 1957, Holman and Kunkel first reported the presence of anti-DNA antibodies, laying the foundation for the role of anti-dsDNA antibodies in SLE research. Over time, anti-dsDNA antibodies have become important markers for SLE, widely used in clinical diagnosis and disease activity monitoring. Anti-dsDNA antibodies are highly pathogenic in SLE patients, particularly evident in lupus nephritis. Lupus nephritis is one of the main causes of morbidity and mortality in SLE, with nearly 80% of lupus nephritis patients having anti-dsDNA antibodies in their serum. These antibodies can bind directly or indirectly to renal antigens, forming immune complexes that trigger inflammatory responses and tissue damage. Anti-dsDNA antibodies can not only penetrate cells and bind to targets but also promote pathological changes by modulating various intracellular factors. In lupus nephritis patients, anti-dsDNA antibodies affect the proliferation and apoptosis of resident renal cells. By regulating the expression of inflammatory cytokines such as IL-6 and TNF-α, anti-dsDNA antibodies further drive the progression of renal damage. Therefore, the production of anti-dsDNA antibodies has become one of the diagnostic criteria for SLE. These research findings provide new insights into the pathogenesis of SLE and offer potential targets for future treatment strategies.

Methods for detecting anti-dsDNA antibodies include Farr radioimmunoassay (FARR-RIA), indirect immunofluorescence test (CLIFT), and enzyme-linked immunosorbent assay (ELISA). Among these, ELISA is particularly suitable for detecting high-affinity anti-dsDNA antibodies in clinical laboratories due to its high sensitivity and specificity. Although anti-dsDNA antibodies are closely related to SLE disease activity, existing detection methods still have certain limitations. For example, some methods may fail to detect low levels of antibodies or immune complexes, necessitating the use of multiple detection techniques to improve accuracy. Recently, researchers have explored novel detection methods, such as using composite histone peptides and short fragments of trypanosome cells, as well as flow-induced dispersion analysis. These new technologies show the potential to enhance detection sensitivity and specificity.

Anti-dsDNA ELISA Kit
dsDNA Autoantibody Detection Kit